Related Experiment Videos
Protection against histamine-induced bronchoconstriction by loratadine
1Clinic for lung diseases, asthma and allergy Auguste-Viktoria- und Cecilienstift, Bad Lippspringe, Germany.
Allergologia Et Immunopathologia
|May 1, 1992
Summary
Loratadine, an H1 histamine receptor antagonist, significantly reduced histamine-induced bronchoconstriction in patients with obstructive lung disease. This study suggests loratadine
Area of Science:
- Pulmonology
- Pharmacology
- Allergy and Immunology
Background:
- Histamine is a key mediator in allergic reactions and can induce bronchoconstriction.
- Obstructive bronchial diseases are characterized by airway hyperreactivity.
- Loratadine is a novel H1 histamine receptor antagonist with potential anti-inflammatory properties.
Purpose of the Study:
- To evaluate the protective effect of loratadine against histamine-induced bronchoconstriction.
- To assess loratadine's efficacy in patients with obstructive bronchial disease and hyperreactivity.
Main Methods:
- A simple blind pilot study design.
- Inclusion of six patients with obstructive bronchial disease and proven bronchial hyperreactivity.
- Two identical histamine inhalation challenges were performed: one without premedication and one after three days of daily 10 mg loratadine treatment.
Main Results:
- The mean fall in Forced Expiratory Volume in 1 second (FEV1) after histamine challenge decreased from 33% without loratadine to 3.3% with loratadine (p < 0.01).
- Five out of six patients experienced complete protection against histamine-induced bronchoconstriction.
- One patient showed partial protection.
Conclusions:
- Loratadine effectively inhibits histamine-induced bronchoconstriction.
- Loratadine demonstrates potential utility in the prophylactic treatment of asthma and obstructive bronchitis.
- Further research is warranted to confirm these findings in larger patient cohorts.